It has been demonstrated that some nonmotor symptoms in MDS‐UPDRS I, like cognitive impairment and autonomic dysfunction, can precede dopamine transporter deficit in nonmanifesting LRRK2 mutation carriers.15 Here, SLC6A3 is linked to Cognitive impairment.